Establishment Labs Holdings (ESTA) drew fresh attention after the FDA cleared an expanded range of Motiva SmoothSilk Round and Motiva SmoothSilk Ergonomix breast implants, adding 28 new sizes for the United States market.
The FDA approval landed alongside a sharp 3.8% one-day share price gain. Establishment Labs Holdings still shows a 30-day share price return down 10.5% and a 90-day share price return down 27%, even as the 1-year total shareholder return is 69%.
Scan for other medical technology stocks reacting to fresh approvals and regulatory catalysts by using the hand picked list of solid balance sheet and fundamentals (25 results), which can complement a position in Establishment Labs Holdings.
Bulls see Establishment Labs Holdings riding fresh FDA momentum and a 69% 1 year return, while bears point to recent share declines and ongoing losses. Which story does the current valuation support?
Most Popular Narrative: 35% Undervalued
On the narrative numbers, Establishment Labs Holdings screens below its implied fair value of $102.44, compared with the recent close at $66.47. This puts the FDA approval into a much bigger context for long term holders.
Accelerating surgeon adoption and utilization curve in the U.S., combined with further account additions and growing patient demand (amplified by patient-driven requests and social media engagement), positions the company for continued strong revenue growth and sustainable market share gains in a large, culturally receptive, and increasingly affluent market.
See why 1 investors see Establishment Labs Holdings as 35% undervalued.
Result: Fair Value of $102.44 (UNDERVALUED)
Still, the bullish story for Establishment Labs Holdings can crack if high SG&A and R&D spending keeps profitability elusive, or if Motiva dependence meets softer surgeon or patient demand.
Find out about the key risks to this Establishment Labs Holdings narrative.
Another View on Establishment Labs Holdings Valuation
That 35% implied discount looks appealing, yet the preferred P/S lens tells a different story. Establishment Labs Holdings trades on a P/S of 8.1x, compared with a fair ratio of 5.5x, the US Medical Equipment sector at 2.7x, and peers at 2.3x. This gap points to real multiple risk if sentiment cools, so which signal do you trust more?
For a closer look at how those sales based ratios stack up, and what they could mean if the market drifts toward the fair ratio, See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
If the mixed mood on Establishment Labs Holdings has you torn, act while the numbers and narratives are fresh and pressure test the story yourself. To see what optimists are focusing on, start with the 3 key rewards.
Looking for more investment ideas beyond Establishment Labs Holdings?
If Establishment Labs Holdings has sparked fresh questions for you, you can broaden your watchlist with a few focused idea sets that match different risk and return profiles.
- Target potential mispricing and look for quality companies that trade below estimated value by scanning the 27 high quality undervalued stocks.
- Explore a stream of cash returns and stress test income ideas by reviewing the 7 dividend fortresses.
- Reduce portfolio volatility and concentrate on steadier performers by filtering candidates through the 31 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com